XPO1 Inhibitor (ATG-010) Plus Chemotherapy per Investigator's Choice for Heavily Pretreated Patients with Relapsed or Refractory (R/R) Peripheral T-Cell Lymphoma (PTCL) and Extranodal NK/T-Cell Lymphoma (ENKTL):: Preliminary Results from a Multicenter, Single-Arm, Phase Ib Study (TOUCH Trial)

被引：3

作者：

Huang, Huiqiang ^{[1
]}

Gao, Yan ^{[1
]}

Zhang, Huilai ^{[2
]}

Zhou, Keshu ^{[3
]}

Wu, Jianqiu ^{[4
]}

Cai, Zhen ^{[5
]}

Jing, Hongmei ^{[6
]}

Fan, Lei ^{[7
]}

Lou, Sai ^{[8
]}

Fei, Yizhou ^{[8
]}

Wang, Aihua ^{[8
]}

Lynch, Kevin ^{[8
]}

机构：

[1] Sun Yat Sen Univ Canc Ctr, Dept Med Oncol, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Guangzhou, Peoples R China

[2] Tianjin Med Univ Canc Inst & Hosp, Dept Lymphoma, Natl Clin Res Ctr Canc, Tianjins Clin Res Ctr Canc, Tianjin, Peoples R China

[3] Zhengzhou Univ, Henan Canc Hosp, Dept Hematol, Affiliated Canc Hosp, Zhengzhou, Peoples R China

[4] Nanjing Med Univ, Jiangsu Inst Canc Res, Dept Med Oncol, Affiliated Canc Hosp, Nanjing, Peoples R China

[5] Zhejiang Univ, Affiliated Hosp 1, Dept Hematol, Bone Marrow Transplantat Ctr,Coll Med, Hangzhou, Zhejiang, Peoples R China

[6] Peking Univ Third Hosp, Dept Hematol & Lymphoma Res Ctr, Beijing, Peoples R China

[7] Nanjing Med Univ, Jiangsu Prov Hosp, Dept Hematol, Collaborat Innovat Ctr Canc Personalized Med,Firs, Nanjing, Peoples R China

[8] Antengene Therapeut Ltd, Shanghai, Peoples R China

来源：

BLOOD | 2021年 / 138卷

关键词：

D O I：

10.1182/blood-2021-147100

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

2452

引用

页数：4

共 30 条

[21] Anti-PD-1-Antibody (Tislelizumab) Combined with Deacetylase Inhibitor (Chidamide), Lenalidomide and Etoposide for the Treatment of Refractory/Relapsed Extranodal Natural Killer/T Cell Lymphoma, Nasal Type (r/r-ENKTL): Preliminary Results from a Prospective, Multicenter, Single -Arm, Phase II Trial
Zhang, Lei
Liu, Xiyang
Wang, Xinhua
Chang, Yu
Fu, Xiaorui
Li, Xin
Li, Ling
Yan, Jiaqin
Nan, Feifei
Wu, Xiaolong
Zhu, Linan
Sun, Zhenchang
Yu, Hui
Zhang, Mingzhi
BLOOD, 2021, 138
[22] Selective PI3K δ Inhibitor Parsaclisib Combined with HDAC Inhibitor Chidamide in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma: Preliminary Results of a Phase Ib/II Study
Yan, Zheng
Yao, Shuna
Zhao, Shuang
Wang, Haiying
Chu, Junfeng
Xu, Yuanlin
Zhang, Jiuyang
Zhang, Lina
Lin, Quande
Liang, Lijie
Wang, Ping
Li, Wenyong
Teng, Xiaolu
Yao, Zhihua
Liu, Yanyan
BLOOD, 2023, 142
[23] y Combination of Chidamide with the CHOEP Regimen in Previously Untreated Patients with Peripheral T-Cell Lymphoma (PTCL): A Prospective, Multicenter, Single-Arm, Phase 1b/2 Trial
Zhang, Wei
Su, Liping
Liu, Lihong
Gao, Yuhuan
Wang, Quanshun
Su, Hang
Song, Yuqin
Zhang, Huilai
Shen, Jing
Jing, Hongmei
Wang, Shuye
Cen, Xinan
Liu, Hui
Liu, Aichun
Li, Zengjun
Luo, Jianmin
He, Jianxia
Wang, Jingwen
O'Connor, Owen A.
Zhou, Daobin
BLOOD, 2019, 134
[24] PD-1 Antibody (Sintilimab) Plus Histone Deacetylase Inhibitor (Chidamide) for the Treatment of Refractory or Relapsed Extranodal Natural Killer/T Cell Lymphoma, Nasal Type (r/r ENKTL): Updates of the Phase Ib/II Scent Study
Yan, Gao
Zhang, Liling
Li, Wenyu
Wei, Xu
Feng, Ru
Li, Xue-Ping
Chen, Yu
Wu, Huijing
Wang, Xiaoxiao
Bai, Bing
Huang, Huiqiang
BLOOD, 2023, 142
[25] Randomized Phase III Study of Alisertib or Investigator's Choice (Selected Single Agent) in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma (vol 14, pg 561, 2019)
Plotkin, S. R.
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06) : 656 - 656
[26] A prospective, multicenter, randomized study of anti-CCR4 monoclonal antibody mogamulizumab (moga) vs investigator's choice (IC) in the treatment of patients (pts) with relapsed/refractory (R/R) adult T-cell leukemia-lymphoma (ATL)
Phillips, Adrienne Alise
Fields, Paul
Hermine, Olivier
Ramos, Juan Carlos
Beltran, Brady Ernesto
Pereira, Juliana
Brites, Carlos
Kurman, Michael R.
George, Joyce
Dwyer, Karen M.
Conlon, Kevin
Taylor, Graham P.
Gonsky, Jason Parker
Horwitz, Steven M.
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[27] Preliminary Results from a Multicenter, Single-Arm, Phase 2 Study of CS1001, an Anti-Programmed Death-Ligand 1 (PD-L1) Human Monoclonal Antibody (mAb), in Patients (pts) with Relapsed or Refractory Extranodal Natural Killer/T Cell Lymphoma (rr-ENKTL)
Huang, Hui-qiang
Tao, Rong
Zou, Liqun
Cen, Hong
Guo, Ye
Huang, Yunhong
Qian, Wenbin
Zhang, Liling
Zhou, Hui
Yang, Yu
Yang, Haiyan
Zhu, Dan
Fang, Teng
Dai, Hangjun
Wang, Yueling
Yang, Jianxin
BLOOD, 2019, 134
[28] PRALATREXATE PLUS BEXAROTENE IN PATIENTS WITH RELAPSED OR REFRACTORY CUTANEOUS T-CELL LYMPHOMA (CTCL): STUDY DESIGN AND PRELIMINARY Results FROM AN ONGOING, OPEN-LABEL, PHASE 1 DOSE-FINDING STUDY
Zinzani, P. L.
Geskin, L.
Kim, Y. H.
Chance, L.
Duvic, M.
HAEMATOLOGICA, 2012, 97 : 651 - 651
[29] Preliminary Results from an Ongoing Phase 2, Open-Label, Multicenter, Single-Arm Study Assessing an Every-4-Week Dosing Schedule of Mogamulizumab in Patients with Cutaneous T-Cell Lymphoma
Scarisbrick, J.
Querfeld, C.
Akilov, O.
Bagot, M.
Cordoba, R.
Cowan, R.
Garcia-Sancho, A. M.
Geskin, L. J.
Huen, A. O.
Jadwani, J.
Liu, Y.
Zhao, H.
Morris, S.
Ortiz-Romero, P. L.
Patel, A.
Pinter-Brown, L. C.
Pujol, R. M.
Quaglino, P.
Saba, N. S.
Vuppugalla, R.
Kim, Y. H.
EUROPEAN JOURNAL OF CANCER, 2024, 211 : S30 - S31
[30] Combination of Oral Nanatinostat (Nstat), a Novel Histone Deacetylase Inhibitor (HDACi), and the Oral Anti-Viral, Valganciclovir (VGCV), Is Active in Relapsed/Refractory (R/R) Epstein-Barr Virus (EBV)-Positive B-Cell, T-Cell, and Hodgkin Lymphoma: Interim Safety and Efficacy Results from a Phase 1b/2a Study
Porcu, Pierluigi
Haverkos, Brad M.
Alpdogan, Onder
Capra, Marcelo
Feldman, Tatyana A.
Brem, Elizabeth
Vallurupalli, Anusha
Brammer, Jonathan E.
Schriefer, Ana
Pereira, Juliana
Tulpule, Anil
Barta, Stefan K.
Bryan, Locke J.
Trauger, Richard
Obrzut, Sebastian
Gutheil, John
Katkov, Afton
McRae, Robert
Royston, Ivor
Faller, Douglas V.
BLOOD, 2019, 134

← 1 2 3 →